Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases

HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announce today that Ascletis' subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license...

from PR Newswire: https://ift.tt/2Ynb96a